Loading…
for educational and safety purposes
Brivaracetam and Etiracetam both come up in the same conversations; they overlap on GABA and Glutamate. Brivaracetam: Brivaracetam is a racetam-derivative antiseizure medication and an analog of levetiracetam, used as add-on therapy for focal, or partial-onset, seizures in people with epilepsy. Etiracetam: Etiracetam is a synthetic compound of the racetam family and a close relative of piracetam.
Brivaracetam is a racetam-derivative antiseizure medication and an analog of levetiracetam, used as add-on therapy for focal, or partial-onset, seizures in people with epilepsy. It was rationally designed as a high-affinity, highly selective ligand of the synaptic vesicle glycoprotein SV2A, binding the target roughly 15 to 30 times more tightly than levetiracetam, and is associated in clinical use with a more favorable behavioral and psychiatric tolerability profile. Developed by the company UCB and marketed as Briviact, it received European and United States approval in 2016.
Etiracetam is a synthetic compound of the racetam family and a close relative of piracetam. It is a racemic mixture whose biologically active enantiomer, the S-form, is levetiracetam, a widely used antiseizure medication; investigation of levetiracetam's mechanism led to the identification of the synaptic vesicle glycoprotein SV2A as its molecular target and as a novel class of antiepileptic drug target. Etiracetam itself was investigated for effects on memory and against seizures but was not marketed, with development focusing instead on its purified active enantiomer.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
binds/modulates
modulates
weakly inhibits
reduces
binds
modulates
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.